603387 Getein Biotech,Inc
- 9.48
- -0.08-0.84%
Getein Biotech,Inc News
Express News | Jiangsu's imports and exports to Hungary increased 16.5% year-on-year in the first quarter
Foundation Egg Biotech (603387.SH) announced first-quarter results, net profit of 86.013,500 yuan, a year-on-year decrease of 29.22%
Foundation Egg Biotech (603387.SH) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 322 million yuan, a year-on-year decrease of 16.32%; net profit attributable to shareholders of listed companies was 86.013,500 yuan, a year-on-year decrease of 29.22%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 827.367 million yuan, a year-on-year decrease of 17.71%; and basic earnings per share were 0.17 yuan.
The disclosure of the annual report of the subsidiary Gidao Biotech was delayed until June, and there may be competition issues in the industry
Gelonghui, April 27 | Since the acquisition of Jingchuan Diagnostics, a company listed on the Shanghai Main Board in 2020, the two have continued to conflict as parent companies and subsidiaries for several years. On April 26, the subsidiary Jingchuan Diagnosis issued the “Notice of Resolutions of the 10th Meeting of the 3rd Board of Directors”. The announcement shows that on April 24, 2024, 5 directors of Jingchuan Diagnosis voted on 12 proposals, including the “Proposal on the Company's 2023 Annual Report and Summary” and the “Proposal on the Company's 2023 Capital Utilization Special Report”.
The lawsuit extends to the rival base of the industry, and the dispute between Egg Biotech and the shareholders of the subsidiary intensifies
① Recently, the small and medium shareholders of Jingchuan Diagnostics were sued by the small and medium shareholders of Jingchuan Diagnostics, and this is only one part of the fight between the two sides; ② Jingchuan Diagnostics made an exclusive response to the Financial Federation reporter saying that several lawsuits have only been filed in August of last year, and that management and employees expect the dispute to be resolved as soon as possible; ③ the industry believes that the intention to continue to acquire Gidao Biotech is not strong, or that it has caused a “soft confrontation” with Jingchuan Diagnosis.
Is Weakness In Getein Biotech, Inc (SHSE:603387) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
With its stock down 20% over the past three months, it is easy to disregard Getein Biotech (SHSE:603387). But if you pay close attention, you might gather that its strong financials could mean that
Getein Biotech, Inc (SHSE:603387) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough
The Getein Biotech, Inc (SHSE:603387) share price has fared very poorly over the last month, falling by a substantial 25%. Instead of being rewarded, shareholders who have already held through the
Retail Investors Among Getein Biotech, Inc's (SHSE:603387) Largest Stockholders and Were Hit After Last Week's 8.1% Price Drop
Key Insights Getein Biotech's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public 50% of the business is held by the top 25 s
Basic Egg Biology (603387): Multi-production line layout and platform-based construction first take shape
Key investment points: Deeply involved in the industry for more than 20 years, speeding up the layout of multiple product lines, and platform-based construction taking shape. At the beginning of its establishment, the company continued to develop in vitro diagnosis, and gradually built a POCT line based on chemiluminescence, coagulation, and flow
BaseEgg Biology (603387.SH): The current luminescence collection project in Anhui accounts for a small proportion of the company's current luminescence reagent project revenue
On November 8, Gelonghui (603387.SH) said at the online performance briefing that judging from the company's chemiluminescence reagent revenue structure, the myocardial category accounts for 85%, and inflammation and tumors account for about 10% in total. At this stage, chemiluminescence mainly focuses on myocardial and inflammation tests. In the future, with the gradual coverage of small assembly line installations, it will drive an increase in testing items such as infectious diseases, hypertonics, and tumors. This time, the Anhui luminescence collection project accounts for a small proportion of the company's current luminescence reagent project revenue, and has little impact on the company's chemiluminescence business.
603387.SH released third quarter results, net profit of 603.497 million yuan, a year-on-year decrease of 58.49%
Kibao Biotech (603387.SH) released its report for the third quarter of 2023, with revenue of 298 million yuan...
Getein Biotech, Inc's (SHSE:603387) Market Cap Dropped CN¥370m Last Week; Individual Investors Bore the Brunt
Key Insights Significant control over Getein Biotech by individual investors implies that the general public has more power to influence management and governance-related decisions A total of 15 inv
Jiegang Biotech (603387.SH) plans to pay 0.1 yuan per share for half a year, excluding interest on September 27
Jiegg Biology (603387.SH) announced that the company plans to distribute a cash dividend of 0.1 yuan per share for the first half year of 2023...
Gi-egg Biology (603387.SH): MAGICL6000 was installed more than 550 units in the first half of the year, and a total of more than 1,500 units have been installed since the product was launched
Gelonghui, September 12丨Gigang Biotech (603387.SH) said at the semi-annual results online briefing that in the first half of 2023, the chemiluminescence business line achieved sales revenue of 917.38,800 yuan, an increase of 262.66% over the previous year. The rapid growth in the chemiluminescence business was mainly due to the continuous release of Xiaoluminescence MAGICL6000. MAGICL6000 has advantages such as “high automation, small size and speed, quick results, and full blood testing”. It was installed more than 550 units in the first half of the year, and has accumulated more than 1,500 units since the product was launched. Of these, hospitals level 2 and above have been installed
Giegg Biology (603387.SH): It is expected that the smart series assembly line METIS800 and fully automatic coagulation analyzer CA5500 will be launched on the market in the second half of this year
GLONGHUI, September 12, Sept. 12, 丨 Ge Egg Biology (603387.SH) said at the semi-annual results online briefing that the company attaches importance to technological innovation and new product development. It is expected to launch the smart series assembly line METIS800 and fully automatic coagulation analyzer CA5500 on the market in the second half of this year; the fully automated biochemical immunity assembly line Metis8000 is being gradually developed according to plan, and the biochemical module, luminescence module and SDM module have completed assembly and debugging of the prototype. It is currently undergoing performance verification and is expected to be launched next year.
Gi Egg Biology (603387.SH): The Metis 6000 fully automatic raw free assembly line developed and produced by itself in the first half of the year. As of August 30, a total of 30 pieces had been installed
GLONGHUI, September 12丨Gigang Biology (603387.SH) said at the semi-annual results online briefing that in the first half of this year, the company officially released the self-developed and self-produced Metis6000 fully automated free production line. As of August 30, 2023, it had installed a total of 30 machines, of which the coverage rate for hospitals level II and above was around 55%. The competitive advantage of Metis6000 is mainly reflected in the following two aspects: On the one hand, the Metis6000 integrates the MagiCl6200 immunization module and the CM-1000 biochemical module, and is equipped with a new SH80 sample processing system and SHC2
Suen Ben, the controlling shareholder of Jiegang Biotech (603387.SH), released the pledge of 5.9 million shares of the company
Jiegang Biotech (603387.SH) announced that the company's controlling shareholder Soonben was terminated on September 8, 2023...
Jiegg Biotech (603387.SH) announced its first half results, with net profit of 169 million yuan, a year-on-year decrease of 48.84%. It plans to distribute 1 yuan for every 10 shares
Jiegg Biology (603387.SH) released the 2023 semi-annual report. During the reporting period, the company achieved operating income...
Earnings Growth of 2.1% Over 5 Years Hasn't Been Enough to Translate Into Positive Returns for Getein Biotech (SHSE:603387) Shareholders
The main aim of stock picking is to find the market-beating stocks. But even the best stock picker will only win with some selections. So we wouldn't blame long term Getein Biotech, Inc (SHSE:603387
The registration date for the 2022 stock distribution of 0.3 yuan per share by Basegang Biology (603387.SH) is June 1
According to the Zhitong Finance App, Basegao Biology (603387.SH) issued an announcement that the company will implement the 2022 annual equity distribution, with a cash dividend of 0.3 yuan (tax included) per share. The equity registration date is June 1.
Basegam Biology (603387.SH): The implementation of the plan to reduce its holdings by a total of 4.6715 million shares of Nanjing Iji has been completed
Gelonghui, May 26, 丨As of the disclosure date of this announcement, Nanjing iGe reduced its holdings by 4.6715 million shares through centralized bidding transactions, accounting for 0.9211% of the company's total share capital. 603387.SH The implementation of Nanjing's basic basic holdings reduction plan has been completed.
Analysis
Price Target
No Data
